Evidence map›Paper›PMID 41676236›Full record

ArticleThe Lancet regional health. Western Pacific2026

Machine learning prediction of 1-year mortality in older patients with heart failure: a nationwide, multicenter, prospective cohort study.

Kanji Yamada, Nobuyuki Kagiyama, Tomoyuki Morisawa, Masakazu Saitoh, Kentaro Iwata, Michitaka Kato, Koji Sakurada, Yuji Kono, Yuki Iida, Masanobu Taya and 3 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kanji YamadaDepartment of Physical Therapy, Faculty of Health Science, Juntendo University, Tokyo, Japan.
Nobuyuki KagiyamaDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tomoyuki MorisawaCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Masakazu SaitohDepartment of Physical Therapy, Faculty of Health Science, Juntendo University, Tokyo, Japan.
Kentaro IwataDepartment of Rehabilitation, Kobe City Medical Center General Hospital, Kobe, Japan.
Michitaka KatoCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Koji SakuradaCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Yuji KonoCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Yuki IidaCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Masanobu TayaCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Yoshinari FunamiCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Kentaro KamiyaCommittee of the J-Proof HF Registry, Japanese Society of Cardiovascular Physical Therapy, Tokyo, Japan.
Tetsuya TakahashiDepartment of Physical Therapy, Faculty of Health Science, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Risk prediction in older adults with heart failure (HF) often depends on conventional clinical variables and does not incorporate direct measures of physical function. This study aimed to develop and validate a machine learning model that integrates routinely collected functional assessments to predict one-year all-cause mortality. Methods: We analyzed data from the J-Proof HF Registry, a nationwide prospective cohort encompassing 96 institutions in Japan. Patients aged ≥65 years who were hospitalized for HF and received a prescription for rehabilitation between December 2020 and March 2022 were included. An eXtreme Gradient Boosting (XGBoost) model was developed using 77 candidate predictors, including demographic, clinical, laboratory, echocardiographic, and directly measured functional variables. Validation employed a leave-one-site-out (LOSO) internal-external framework. Discrimination, calibration, and clinical utility were compared with established risk scores. A 20-predictor model was derived using SHAP-based importance and clinical review. Findings: Among 9700 eligible patients, the median age was 83 years (interquartile range [IQR] 77-88), 4915 (50.7%) were male, and 1601 (16.5%) died within one year. The full XGBoost model achieved an aggregated area under the receiver operating characteristic curve (AUC) of 0.76 (95% confidence interval [CI] 0.75-0.77) across LOSO test sets. The 20-predictor XGBoost model demonstrated similar discrimination (AUC 0.76; 95% CI 0.74-0.77). Both models outperformed the AHEAD and BIOSTAT compact scores. Functional measures at discharge, including Barthel index, the Short Physical Performance Battery, gait speed, and handgrip strength, were among the strongest contributors to model predictions. Reclassification metrics and decision curve analysis indicated greater clinical utility compared with benchmark scores. Interpretation: A machine learning model incorporating functional assessments predicts one-year mortality in older patients with HF and improves risk stratification beyond established scores. Functional status at discharge is an important prognostic indicator and may inform post-discharge care planning. Funding: This work was supported by research funding of Japanese Society of Cardiovascular Physical Therapy and JSPS KAKENHI Grant Number JP25K02969.

Indexed as

AgedHeart failureMachine learningPhysical functionPrognosis

Identifiers

PMID41676236
PMCPMC12887764

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.